Strategic Investments in the EU and US strengthen Vetter’s Global Footprint
• Building permit application for German site submitted
• Construction start is scheduled for the 2nd quarter 2026, with operational readiness in 2031
• Expansions in the US and Europe are included in a €1.5 billion investment plan
Ravensburg, January 29, 2026: Vetter, one of the world's leading pharmaceutical service providers for the production of injectable drugs, has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany. This strategic investment marks a significant milestone in the company’s long-term global growth strategy. Construction is scheduled to begin in the second quarter of 2026. Initially, approximately €480 million have been allocated for the first construction phase of the new commercial production plant. Operations are expected to commence in 2031.
The Contract
Development and Manufacturing Organization (CDMO) acquired the approximately 95-acre
industrial property in the city of Saarlouis at the end of 2024. This location
was chosen following careful strategic investment considerations and supported
by significant regional advantages. Vetter sees the potential to create up to
2,000 jobs in the long term. The European Commission has approved up to €47 million
of state aid for this extensive project.
"With the
construction of our new production facility in Germany, we continue on our path
to sustainable growth. Long-term success derives from striking the right
balance between stability and expansion," emphasizes Senator h.c. Udo J.
Vetter, Chairman of the Advisory Board and member of the owner family. “With
our investments in the state of Saarland, only a five hour drive away from our
headquarters in Ravensburg, we are strengthening our commitment to Germany’s
economic landscape while reaffirming our engagement as a strategic partner to
the global pharmaceutical market.”
In parallel, the
company recently began construction on a new clinical production site in Des
Plaines, Illinois, USA. This new aseptic manufacturing facility emphasizes
Vetter’s commitment to providing high-quality services and drug products during
early clinical development.
For over 75 years,
Vetter has been committed to quality, innovation, and responsibility in the
production of sterile pharmaceuticals, improving the lives of patients
worldwide. To meet growing customer demand and increasing market requirements,
the company is investing in its existing sites in Germany, Austria, and the
United States. With its newly planned commercial site, Vetter will significantly
expand its production capacity.
© Vetter Pharma
International GmbH: Aerial view of the 95-acre industrial site (marked) in southwest
Germany acquired by Vetter for a new commercial production facility.
Picture source Saarland State Chancellery
/ Jennifer Weyland: Minister-President of
Saarland Anke Rehlinger and Senator h.c. Udo J. Vetter, Chairman of the
Advisory Board and member of the owner family, with the model of the new,
multi-phase production site in Saarlouis. About Vetter Vetter is a leading Contract Development and Manufacturing
Organization (CDMO) with headquarters in Ravensburg, Germany, and production
facilities in Germany, Austria, and the US. As a global player, the independent
pharmaceutical service provider is also present in the Asia-Pacific markets of
Japan, China, South Korea and Singapore with sales locations. Around the world,
renowned pharma and biotech companies benefit from decades of experience, high
quality, modern technologies, reliability, and commitment of its more than 7,700 employees. In close collaboration
with its customers, the Vetter team helps enable the supply to patients all
over the world with medicines, many of which are vital. The CDMO provides
support from drug product development through clinical and commercial filling
to a wide range of assembly and packaging services for vials, syringes, and
cartridges. With innovative approaches, Vetter develops prefilled drug-delivery
systems together with its customers to continuously improve patient safety,
comfort, and compliance. Vetter
takes responsibility for sustainable practices and operates as a socially and
ethically responsible corporate citizen. The CDMO is a member of the UN
Global Compact and Science Based Target initiative (SBTi) and
received platinum status in the renowned EcoVadis ranking. Multiple awards such
as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership
Award and the recognition
of Best Managed Company emphasize Vetter’s commitment to sustainable
business. Founded in Ravensburg in 1950, the company remains family-owned to
this day. For more information, visit www.vetter-pharma.com and follow
Vetter on LinkedIn.
Contact Vetter Pharma
International GmbH Markus Kirchner Corporate Spokesperson /
Media Relations Eywiesenstrasse 5 88212 Ravensburg Germany Phone: +49
(0)751-3700-3729 E-mail: PRnews@vetter-pharma.com
